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EFFECTIVENESS OF STEVIA REBAUDIANA WHOLE LEAF EXTRACT 
AGAINST THE VARIOUS MORPHOLOGICAL FORMS OF BORRELIA 
BURGDORFERI IN VITRO
P. A. S. Theophilus, M. J. Victoria, K. M. Socarras, K. R. Filush, K. Gupta, D. F. Luecke, E. Sapi*
Department of Biology and Environmental Science, University of New Haven, West Haven, CT, USA
Received: September 7, 2015; Accepted: October 26, 2015
Lyme disease is a tick-borne multisystemic disease caused by Borrelia burgdorferi. Administering antibiotics is the primary treat-
ment for this disease; however, relapse often occurs when antibiotic treatment is discontinued. The reason for relapse remains un-
known, but recent studies suggested the possibilities of the presence of antibiotic resistant Borrelia persister cells and biofilms.
  In this study, we evaluated the effectiveness of whole leaf Stevia extract against B. burgdorferi spirochetes, persisters, and bio-
film forms in vitro. The susceptibility of the different forms was evaluated by various quantitative techniques in addition to differ-
ent microscopy methods. The effectiveness of Stevia was compared to doxycycline, cefoperazone, daptomycin, and their combina-
tions. Our results demonstrated that Stevia had significant effect in eliminating B. burgdorferi spirochetes and persisters. Sub-
culture experiments with Stevia and antibiotics treated cells were established for 7 and 14 days yielding, no and 10% viable cells, 
respectively compared to the above-mentioned antibiotics and antibiotic combination. When Stevia and the three antibiotics were 
tested against attached biofilms, Stevia significantly reduced B. burgdorferi forms. Results from this study suggest that a natural 
product such as Stevia leaf extract could be considered as an effective agent against B. burgdorferi.
Keywords: Borrelia burgdorferi, biofilms, persister cells, Stevia rebaudiana, antibiotic resistance
Abbreviations: ATCC – American type culture collection; BSK-H – Barbour–Stoner–Kelly H; CefP – cefoperazone; DapM – 
daptomycin; DoxC – doxycycline; EPS – extracellular polymeric substances; Log phase – logarithmic phase; PBS – phosphate 
buffered saline; PI – propidium iodide; PTLDS – post-treatment Lyme disease syndrome
Introduction
Lyme disease is a leading tick-borne multisystemic dis-
ease caused by the spirochete Borrelia burgdorferi. The 
bacterium is transmitted by Ixodes ticks, which could feed 
on white-footed mice, rodents, deer, and birds [1, 2]. In 
the United States, there are approximately 300,000 people 
diagnosed with Lyme disease each year [3]. The frontline 
treatment for Lyme disease is antibiotics such as doxycy-
cline for adults and amoxicillin for children [4–8]. These 
antibiotics are found effective in most cases of patients 
diagnosed with Lyme disease [5–8]. However, accord-
ing to the Centers for Disease Control (CDC), approxi-
mately 10–20% of the Lyme disease patients treated with 
anti biotics for a recommended 2 to 4 weeks experienced 
symptoms of fatigue, pain or joint and muscle aches [9]. 
In some patients, the symptoms even lasted for more than 
6 months [9]. This condition was termed as “post-treat-
ment Lyme disease syndrome (PTLDS)” or “chronic Lyme 
disease” [9].
The mechanism associated with this condition in pa-
tients remains unclear. Though not proven, there are a cou-
ple of suggested explanations, such as the inability of the 
immune system to completely clear B. burgdorferi persist-
ers [10], or due to the presence of antigenic debris, which 
might cause immunological responses [11]. Another possi-
bility of Borrelia evading the host immune clearance after 
antibiotic treatment is not well understood [12, 13].
Previous in vivo studies on mice, dogs, and nonhuman 
primates have shown that B. burgdorferi could not be fully 
eliminated by various antibiotics such as doxycycline, cef-
triaxone, and tigecycline. Also, a recent study had demon-
strated the presence of Borrelia DNA in mice following 12 
months of antibiotic treatment [14]. However, the culturing 
of viable organisms in Borrelia growth media could not be 
achieved in these studies [14–17]. A recent study reported 
the presence of Borrelia DNA from a patient with PTLDS 
after antibiotic treatment [18]. Prospective clinical stud-
ies demonstrated no signifi cant effective antibiotic therapy 
and failed to show evidence of the continued presence of 
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B. burgdorferi in patients with long-term symptoms [19, 
20]. Other trials using prolonged intravenous ceftriaxone 
treatment only improved fatigue symptoms [21]. In sum-
mary, fi ndings suggest that conventional treatments may 
not completely eliminate Borrelia persisters.
The life style of B. burgdorferi is complex as it ex-
ists in different morphological forms like the spirochetes, 
spheroplast (or L-form), round bodies, and biofi lms [7, 13, 
22–25]. Several studies show that Borrelia can change into 
round bodies when conditions become unfavorable such 
as changes in temperature, high or low pH, starvation, an-
tibiotic exposure, and/or even an attack from the immune 
system [7, 23–25]. Borrelia in these defensive forms be-
comes dormant, immobile, and remains in this morpho-
logical state until it fi nds favorable conditions to return to 
its spirochete form [7, 22, 24, 26]. The most effective hid-
ing place proposed for B. burgdorferi is the recently sug-
gested biofi lm form [24]. Bacterial biofi lms are organized 
communities of cells enclosed in a self-produced hydrated 
polymeric matrix or extracellular polymeric substances 
(EPS), which is a complex mixture of polysaccharides, lip-
ids proteins, nucleic acids, and other macromolecules [24, 
27]. This unique matrix protects the underlying cells from 
antimicrobial agents [24, 27]. Elimination of pathogenic 
bacteria in their biofi lm form is very challenging since 
these sessile bacterial cells can endure the host immune 
responses and are much less susceptible to antibiotics or 
any other biocides than their individual planktonic coun-
terparts [24, 27]. Biofi lm resistance is based upon multiple 
mechanisms, such as phenotypic changes of cells form-
ing in the biofi lm, the expression of effl ux pumps, and the 
presence of persister cells, which resist killing when ex-
posed to antimicrobial agents [28, 29].
Recently, we provided evidence that B. burgdorferi is 
capable of forming biofi lms in vitro [24]. The aggregation 
of spirochete and round body forms with several differ-
ent protective layers which makes up the biofi lm and ex-
tracellular polymeric substances (EPS) is proposed to be 
a signifi cant factor in antibiotic resistance [24]. It is also 
reported that the biofi lms have higher population of the 
persister cells, which could lead to the antimicrobial resis-
tance portrayed by these forms [24, 29].
Our previously published results on the in vitro effects 
of doxycycline on B. burgdorferi showed that different 
morphological forms have unique sensitivities to antimi-
crobial agents [7]. A recent study by J. Feng et al. showed 
that doxycycline was effective in reducing the spirochetes 
but not the persisters of B. burgdorferi [30, 31]. Studies 
have also showed that doxycycline and amoxicillin could 
eliminate the spirochetal form of B. burgdorferi, but the 
dormant persisters/biofi lm-like aggregates/microcolonies 
were not susceptible to these antibiotics [7, 31]. There-
fore, there is an urgent need to fi nd effective agents, which 
can target/eliminate all the morphological forms of Bor-
relia.
Natural antimicrobial agents, which have been used for 
thousands of years, have been shown to be effective against 
various pathogens [32]. Many in vitro and clinical stud-
ies have demonstrated their effectiveness not only against 
B. burgdorferi but also against many other pathogens 
[33–38]. Stevia rebaudiana which belongs to the Astera-
ceae family is typically referred to as honey leaf or sweet 
leaf, and due to its natural sweetness, it is used as a natural 
substitute to synthetic sweetener [39–41]. The leaf extract 
of Stevia possesses many phytochemicals, which include 
austroinullin, β-carotene, dulcoside, nilacin, rebaudi ox-
ides, ribofl avin, steviol, stevioside, and tiamin with known 
antimicrobial properties against many pathogens [40, 42, 
43]. The role of these compounds is mainly to protect the 
plant from microbial infection and adverse environmental 
conditions [38–43]. Stevia is also well known in tradition-
al medicine for its use in treatment of many diseases like 
diabetes, high blood pressure, and weight loss [44, 45]. In 
a few clinical studies, it is reported that the phytochemical 
stevioside reduces blood pressure in patients experienc-
ing mild hypertension and reduces blood glucose levels in 
type 2 diabetic patients [44, 45]. It was also demonstrated 
that the patients did not encounter any adverse effects from 
the use of stevioside [44, 45].
Considering the effectiveness of Stevia leaf extract in 
laboratory and clinical studies, we evaluated the antimi-
crobial potential of Stevia (whole leaf extracts) against the 
Lyme disease causing pathogen, B. burgdorferi, in a goal 
to eliminate all the different morphological forms in vitro. 
To effectively evaluate the whole Stevia leaf extract, we 
compared the antimicrobial effect of Stevia with antibi-
otics (doxycycline, cefoperazone, daptomycin) and their 
combination, which were recently found effective against 
Borrelia persisters.
Materials and methods
Bacterial culture conditions and media requirements
Low passage isolates (≤ 8) of B. burgdorferi strain B31 
were obtained from the American Type Culture Col-
lection (ATCC 35210) and were cultured in Barbour–
Stoner–Kelly H (BSK-H) media (Sigma, St Louis, MO) 
supplemented with 6% rabbit serum (Pel-Freez®, Rogers, 
AR). The antibiotic free cultures were maintained in ster-
ile 15 ml glass tubes and incubated at 33 °C with 5% CO2. 
For logarithmic (log) phase, 1 × 105 cells/ml were seeded 
in glass tubes and allowed to grow for 5 days. The ef-
fectiveness of the antimicrobial agents on the logarithmic 
phase was tested by inoculating 1 × 105 spirochetes/ml 
from the fi ve-day grown culture (containing only spiro-
chetes) in 90 μl of BSK-H media in 96-well tissue culture 
plates (BD Falcon, Franklin Lakes, NJ), which were in-
cubated for 5 days at 33 °C with 5% CO2. The cells were 
treated with antimicrobial agents for 3 days after a two-
day incubation period. Likewise, for the stationary phase, 
1 × 105 cells/ml were seeded in glass tubes and allowed to 
grow for 7 days. The effectiveness of the antimicrobial 
agents was tested by inoculating 1× 106 spirochetes/ml in 
90 μl of BSK-H media in a 96-well tissue culture plate, 
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which was incubated for 8 days at 33 °C with 5% CO2. 
The persister cells in stationary phase were treated with 
antimicrobial agents for 3 days after 5 days of incubation. 
Biofi lms were generated by inoculating 5 × 106 cells/ml 
of Borrelia spirochetes in 1 ml of BSK-H media in four-
well chamber slides (Thermo Scientifi c, Waltham, MA) or 
plastic/collagen-coated tissue culture 48-well plates (BD 
Falcon), which were incubated for 7 days at 33 °C with 
5% CO2. The treatment regime for the biofi lms was the 
same as that for the stationary phase.
Compounds and antibiotic preparation
Different Stevia extracts manufactured by Nutramedix®, 
Now®, Sweet leaf®, and Truvia® were purchased from 
health food stores in the USA and were labeled randomly 
as Stevia A, B, C, and D. The extracts A, B, and C were 
formulated by standard alcohol extraction method where-
as extract D was purchased in a powder form dissolved 
in distilled water. Stevioside (Sigma) was prepared in 
0.001% DMSO and further diluted in 1× phosphate buff-
ered saline (PBS, 0.1 M, pH 7.4 from Sigma). The antibi-
otics doxycycline, cefoperazone, and daptomycin (Sigma) 
at a concentration of 10 μg/ml were prepared in PBS. All 
antimicrobial agents were sterilized using a 0.2-μm fi lter 
unit (EMD Millipore, Billerica, MA). The antibiotic solu-
tions were aliquoted and stored at minus 20 °C.
Determining the protein concentrations
of the antimicrobial agents
Since the concentration of the antimicrobial components 
in the Stevia extracts A, B, C, and D were unknown, the 
concentration units used initially involved the use of part 
of solute per 50 parts of solution (1:50 dilution). The pro-
tein content of antimicrobial agents was determined by 
Bradford assay (Sigma) using serial dilutions of 2 mg/ml 
of bovine serum albumin stock (Sigma) in PBS pH 7.4 as 
a standard. Bradford reagent was added to the antimicro-
bial agents according to the manufacturer’s instructions 
and incubated for 10 min at room temperature with gentle 
shaking. The absorbance was measured at 595 nm using a 
BioTek spectrophotometer.
In vitro antimicrobial susceptibility testing
of  B. burgdorferi
The effective antibiotics and the antibiotic combination 
identifi ed [30] were tested to compare and evaluate the 
effectiveness of Stevia on B. burgdorferi. As a positive 
control, doxycycline (10 μg/ml) was used. As a negative 
control, 1× PBS at pH 7.4 was used to dissolve antibiot-
ics and 25% alcohol (Fisher Scientifi c, Pittsburg, PA) was 
used since all the Stevia extract contained the same alcohol 
diluent.
SYBR Green I/PI assay
To evaluate live and dead cells, standard SYBR Green I/
propidium iodide assay (SYBR Green I/PI) was per-
formed as previously described [30, 31, 46, 47]. To 
1 ml of sterilized distilled water, 10 μl of SYBR Green I 
(10,000× stock, Invitrogen, Grand Island, NY) and 30 μl 
of propidium iodide (Thermo Scientifi c) were briefl y 
mixed. The staining mixture (10 μl) was added to all the 
wells containing B. burgdorferi and was incubated in the 
dark for 15 min. The plates were measured using a fl uo-
rescent reader (BioTek FLx800) by setting the excitation 
wavelength at 485 nm and the absorbance wavelength 
at 535 nm (green emission) and 635 nm (red emission). 
The standard equation was determined from 1 × 106 cells 
(logarithmic phase), 5 × 106 cells (stationary phase), and 
1 × 107 cells (7 days and 14 days subculture). A live and 
dead population was prepared. For the dead cell popula-
tion, the cells were killed by adding 300 μl of 70% iso-
propyl alcohol (Fisher Scientifi c). B. burgdorferi suspen-
sions at different ratios of live/dead cells (0:10, 2:8, 5:5, 
8:2, 10:0) were added to the wells of the 96-well plate 
accordingly. The staining mixture was added to each of 
the fi ve samples, and the plate was read as above. Us-
ing least square fi tting analysis, the regression equation 
was calculated between the percentage of live bacteria 
and green/red fl uorescence ratios. The regression equa-
tion was used to calculate the percentage of live cells in 
each sample of the screening plate. Also, images of the 
treated sample were taken using fl uorescent microscopy 
(Leica DM2500).
Total viable counts of  B. burgdorferi
As a confi rmation test, the SYBR Green/PI stained cul-
tures were assessed for cell growth by directly counting 
live and dead bacteria using a bacterial counting chamber 
(Hausser Scientifi c, Horsham, PA) and fl uorescent micro-
scopy (Leica DM2500). As above, using least square fi tting 
analysis, the regression equation was calculated between 
the percentage of live bacteria and green/red fl uorescence 
ratios. The regression equation was used to calculate the 
percentage of live cells in each sample.
Long-term subculture experiments to assess viability
of treated B. burgdorferi stationary phase culture
To assess if the treated stationary phase cultures can re-
grow in fresh media, 96-well plates were fi lled with 100 
μl of fresh BSK-H media. From the treated stationary 
phase cultures, 1:75 dilution of treated stationary phase 
culture was added to a sterile 96-well plate (BD Falcon) 
containing 100 μl of fresh BSK-H media and incubated 
for 7 days and 14 days without antimicrobial treatment. 
Following incubation, the viability was assessed using the 
SYBR Green I/PI assay and direct counting method.
In vitro effect of Stevia on Borrelia burgdorferi
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Crystal violet biofilm assay
The effi cacy of the antimicrobial agents on biofi lms was 
determined by quantifying the total biomass using crystal 
violet staining. Following incubation, the media was slow-
ly discarded leaving behind the attached biofi lms on the 
surface of the plate. The attached biofi lms were collected 
by adding 500 μl of PBS (0.1 M, pH 7.4) to the samples. All 
centrifugation steps were performed at 12,000 × g at room 
temperature. Biofi lms were pelleted for 5 min, and the su-
pernatant was discarded. A volume of 50 μl (0.01%) crystal 
violet (Sigma) was added to the pellet, and the mixture was 
incubated for 15 min at room temperature. The unbound 
stain was removed by pelleting the biofi lms for 5 min and 
by discarding the supernatant. The pellet was washed with 
200 μl PBS and again pelleted for 5 min. The supernatant 
was discarded in addition to adding 200 μl of 10% acetic 
acid (Sigma) to the pellet to release and dissolve the stain. 
The samples were then incubated at room temperature for 
15 min. Biofi lms were pelleted for 5 min prior to extracting 
the crystal violet stain from the biofi lms, which were trans-
ferred to a 96-well plate, and absorbance was measured at 
595 nm using a BioTek spectrophotometer.
Live/dead bacterial staining technique
To visualize the antimicrobial sensitivity of biofi lms, the 
treated biofi lms were stained using SYBR Green (Invitro-
gen) and propidium iodide (Thermo Scientifi c). The stains 
were prepared as per the SYBR Green I/PI assay proto-
col. To each well of the chamber slide, 5 μl of the stain-
ing mixture was added and allowed to incubate in the dark 
for 15 min. The media was removed carefully not to dis-
turb the attached biofi lm. Slides were cover slipped, and 
images were taken using fl uorescent microscopy (Leica 
DM2500).
Atomic force microscopy
To visualize the morphology of the antimicrobial treated 
biofi lms grown on glass chamber slides (Thermo Scien-
tifi c), the media was carefully removed without disturbing 
the biofi lm. Contact mode AFM imaging in air was per-
formed on a Nanosurf Easyscan 2 AFM (Nanosurf) using 
SHOCONG probes (APPNANO). Images were processed 
using Gwyddion software (Nečas and Klapetek).
Statistical analysis
Statistical analysis was performed using two-tailed 
Student’s t-test (Microsoft Excel, Redmond, WA) and 
graphed using GraphPad Prism® 6.0 (La Jolla, CA). All 
experiments were performed a minimum of three separate 
times with at least three samples per experiment. Data was 
normalized to the control and presented as the mean ± SD.
Results
In this study, we compared and evaluated the antimicrobial 
effect of S. rebaudiana whole leaf extract along with the 
antibiotics doxycycline, cefoperazone, and daptomycin 
on the different morphological forms (spirochetes, round 
bodies, and biofi lms) of B. burgdorferi. We used a recently 
developed high throughput screening method [30, 31, 46] 
to assess the viability of the log phase and stationary phase 
B. burgdorferi after the different antimicrobial treatments 
(quantitatively and qualitatively) in conjunction with di-
rect counting methods as described in our previous pub-
lication [7]. Similar to recent studies, we have evaluated 
both the log phase B. burgdorferi cultures which consist of 
individual spirochetes, the stationary phase cultures which 
consist of the persister cells, and the most resistant form 
of B. burgdorferi, the attached surface biofi lms. Finally, 
atomic force microscopy was used in conjunction with the 
aforementioned methods, to visualize changes in the mor-
phology in attached biofi lms before and after antibiotic 
treatments.
Preliminary screening of different Stevia extracts
Here, we fi rst evaluated four different commercially ob-
tained Stevia extracts (3 alcohol extracts and one extract 
in powder form) and the purifi ed Stevioside on B. burg-
dorferi to fi nd the most effective agent for further studies 
using the SYBR Green/PI assay. The protein concentra-
tion of the four Stevia leaf extracts was determined by a 
standard Bradford assay and ranged from 1.2 μg/ml to 
1.9 μg/ ml. Stevioside was tested at concentration from 100 
to 1000 μg/ml, concentration as suggested from a previous 
study [42].
Fig. 1. Preliminary screening of four different extracts of Stevia 
and Stevioside on the stationary phase of B. burgdorferi after a 
three-day treatment using the SYBR Green/PI assay. n = 3 ± SD, 
*p ≤ 0.05, **p ≤ 0.01 compared to the control
P. A. S. Theophilus et al.
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For the prescreening experiments, we have pretested 
all agents on the log and stationary phase Borrelia cul-
tures at different concentrations using the SYBR Green/
PI assay. Our results showed that Stevia A, Stevia B, and 
Stevia C alcohol extracted agents had signifi cant effects 
on the viability of Borrelia cells, but Stevia D, powdered 
form, and Stevioside did not show any signifi cant effect 
on both the log phase and the stationary phase cells. Fig-
ure 1 shows a representative experiment demonstrating 
that the alcohol extracted based Stevia agents (A, B, C) 
were the most effective against the Borrelia persisters, 
while the powder form of Stevia leaf extract (D) and 
Stevioside had no effect on those resistant cells. Fur-
thermore, Stevia A showed the most promising effect in 
all experiments, and therefore, Stevia A was used in the 
subsequent experiments on the different morphological 
forms of B. burgdorferi.
Fig. 2. Susceptibility of log phase (5 days) and stationary phase (8 days) Borrelia burgdorferi to antimicrobial agents after a three-day 
treatment determined by (A) SYBR Green I/PI assay, (B) direct counting of live and dead cells stained using a mixture of SYBR Green 
I and propidium iodide using fluorescent microscopy. (C) Representative live/dead images of log and stationary phase B. burgdorferi 
to antimicrobial agents taken at 200× magnification (Scale bar − 100 μm). Doxycycline (DoxC) was used as a positive control. 1× 
PBS and 25% alcohol were used as negative controls, respectively. All antibiotics individually as well as in combination were used 
at a concentration of 10 μg/ml. Stevia A was used at a concentration of 1.2 μg/ml. n = 3 ± SD, *p ≤ 0.05, **p ≤ 0.01 compared to the 
control. n = 3 ± SD, +p ≤ 0.05, ++p ≤ 0.01 (doxycycline compared to Stevia A). n = 3 ± SD, *p ≤ 0.05, **p ≤ 0.01 (doxycycline compared 
to Stevia A). Abbreviations: doxycycline – DoxC, cefoperazone – CefP, daptomycin – DapM
In vitro effect of Stevia on Borrelia burgdorferi
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Stevia as a potential agent in eliminating different forms 
of  B. burgdorferi
To compare and evaluate the effectiveness of Stevia on 
B. burgdorferi, recently identifi ed potential antibiotics and 
their combinations were tested along with Stevia A extract 
using the SYBR Green I/PI assay on both log and station-
ary phase cultures. Appropriate amounts of 1× PBS pH 7.4 
and 25% alcohol were used as negative controls.
According to the SYBR Green I/PI assay and the live/
dead images, treatment with 1× PBS or 25% alcohol did 
not signifi cantly reduce the viability of the spirochete rich 
log phase culture and persisters rich stationary cultures 
compared to the control (Fig. 2A, and 2C: panels i–iii and 
ix–xi). Figure 2C: panels i–iii and ix–xi demonstrated that 
the control B31 culture, 1× sterile PBS, and 25% alcohol 
treated cultures comprised only live cells (green).
In the next set of experiments, we tested several previ-
ously reported effective antibiotics on B. burgdorferi such 
as doxycycline, cefoperazone, and daptomycin individu-
ally and in combinations [30, 31].
Doxycycline, as reported earlier [30, 31] was signifi -
cantly able to reduce the viability of log phase B. burg-
dorferi by ~99% compared to the control (Fig. 2A, and 
2C: panel iv). However, doxycycline treatment had no sig-
nifi cant effect on the cells in the stationary phase cultures 
as observed by increasing proportion of viable cells after 
antibiotic exposure compared to the control (Fig. 2A, and 
2C: panel xii).
Cefoperazone at 10 μg/ml, which was previously iden-
tifi ed as one of the drugs with high activity against Borre-
lia persisters [30, 31], signifi cantly reduced the log phase 
viability of Borrelia by ~99% (Fig. 2A, and 2C: panel v) 
but, in contrast, only reduced the stationary phase viability 
by ~18% compared to the control (Fig. 2A). A large popu-
lation of live round body forms and a mixture of live and 
dead spirochetal cells were observed in stationary phase 
culture (Fig. 2C: panel xiii).
Daptomycin, one of the other drugs previously identi-
fi ed with potent activity against Borrelia persisters [30, 31], 
also signifi cantly reduced the live spirochetal enriched log 
phase culture by ~23%, but it was less sensitive in reduc-
ing viable cells in the stationary phase (~16% reduction 
of live cells) compared to the control (Fig. 2A). Images 
demonstrated that cells treated with daptomycin, both log 
and stationary phase show more live cells than dead cells 
(Fig. 2C: panels vi and xiv) compared to control.
A recent study reported that the combination of doxy-
cycline, cefoperazone, and daptomycin successfully elim-
inated both spirochetes and persisters [30]. Our data from 
this study also confi rmed the effectiveness of these three-
antibiotic combination on B. burgdorferi by signifi cantly 
eliminating the live log phase spirochetes (100% effect) 
and also signifi cantly reduced the viability of the station-
ary phase culture by ~86% (Fig. 2A, and 2C: panels vii 
and xv).
In these experiments, we also tested potential anti-
microbial agent Stevia A as an individual agent and com-
pared its effectiveness to the individual antibiotics and the 
three-antibiotic combination. In Fig. 2A, and 2C: panels 
viii and xvi, Stevia A signifi cantly eliminated the log phase 
spirochetes and the stationary phase persisters compared 
to the control (100% effect for both). The log phase and 
the stationary phase culture treated with Stevia A had only 
dead cells (Fig. 2C: panels viii and xvi).
In Fig. 2A, the effectiveness of doxycycline and the 
three-antibiotic combination was compared with Stevia A. 
A signifi cant elimination (p value ≤ 0.01) in the persisters 
was found with Stevia A compared to doxycycline.
Direct counting confirms the effectiveness of Stevia A
on the log phase spirochetes and stationary phase rich 
persisters
To further validate the effectiveness of the antimicrobial 
agents evaluated using the SYBR Green I/PI assay, direct 
counting was performed as described previously [7, 31].
According to the direct counting method, the nega-
tive controls, 1× sterile PBS and 25% alcohol, did not 
signifi cantly reduce the number of viable cells in both 
the log phase and stationary phase compared to the con-
trol (Fig. 2B). While doxycycline signifi cantly reduced 
the log phase viability of Borrelia by ~98%, it did not re-
duce the stationary phase viability compared to the control 
(Fig. 2B). Cefoperazone was also signifi cantly able to re-
duce the viability of log phase Borrelia by ~99% (Fig. 2B), 
whereas cefoperazone in the stationary phase cultures was 
less effective (~32% reduction) in eliminating the persist-
ers as observed by increasing proportion of remaining vi-
able cells after antibiotic exposure compared to the control 
(Fig. 2B, and 2C: panel xiii). Daptomycin, signifi cantly 
reduced the live spirochetal enriched log phase culture by 
~44% and also signifi cantly reduced the stationary phase 
by ~42% compared to the control (Fig. 2B). The three-
antibiotic combination of doxycycline, cefoperazone, and 
daptomycin signifi cantly eliminated the log phase culture 
and also the stationary phase culture by ~84% compared to 
the control (Fig. 2B). The potent antimicrobial agent, Ste-
via A, signifi cantly eliminated the log phase spirochetes 
and signifi cantly reduced the persisters by ~94% (Fig. 2B).
In Fig. 2B, the effectiveness of doxycycline and the 
three-antibiotic combinations was compared with Ste-
via A. A signifi cant reduction (p value ≤ 0.01) in the per-
sisters was found with Stevia A compared to doxycycline.
Effectiveness of Stevia A after a 7-day and 14-day
subculture of antimicrobial treated B. burgdorferi
In the above-mentioned experiments, we have demon-
strated the effectiveness of Stevia A on both spirochetes 
and the persisters of Borrelia and provided data that its 
signifi cant effect is very comparable to the three-antibiotic 
combination reported previously [31]. To confi rm the ef-
fectiveness of Stevia on the persisters, we performed a 
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7-day and 14-day subculture experiment in fresh BSK-H 
medium to observe if the persisters, if any, still left in the 
culture, could regrow in fresh medium assayed by the 
SYBR green I/PI and the direct counting methods.
As expected, the treatment with negative controls, 1× 
PBS and 25% alcohol, was able to successfully repopulate 
the media with predominating green live cells similar to 
the untreated B31 control after a 7- and 14-day subcul-
ture (Fig. 3A, and 3C: panels i–iii and ix–xi). The three-
antibiotic combination and cefoperazone resulted in 5–7% 
of viable cells after a 7-day subculture, but there was a 
signifi cant 14% increase in the number of viable cells 
treated with cefoperazone and a 11% increase in viable 
cells treated with the three-antibiotic combination after a 
14-day subculture (Fig. 3A, and 3C: panels v, vii, xiii, and 
xv). There was a signifi cant 13% and 53% increase in vi-
able cells from the sample treated with doxycycline after 
a 7-day subculture and a 14-day subculture, respectively 
(Fig. 3A, and 3C: panels iv and xii). The treatment with 
daptomycin, however, produced predominating live cells 
Fig. 3. A 7-day and 14-day subculture of 8-day-old Borrelia burgdorferi stationary phase culture treated with antimicrobial agents 
determined by (A) SYBR Green I/PI assay and direct counting of live and dead cells stained using a mixture of SYBR Green I and 
propidium iodide using fluorescent microscopy. (B) Representative live/dead images of a 7-day-old subculture on stationary phase 
B. burgdorferi treated with antimicrobial agents taken at 200× magnification (Scale bar − 100 μm). Doxycycline (DoxC) was used as 
a positive control. 1× PBS and 25% alcohol were used as negative controls respectively. n = 3 ± SD, *p ≤ 0.05, **p ≤ 0.01 compared 
to the control. n = 3 ± SD, +p ≤ 0.05, ++p ≤ 0.01 (doxycycline compared to Stevia A). n = 3 ± SD, *p ≤ 0.05, **p ≤ 0.01 (doxycycline 
compared to Stevia A). Abbreviations: doxycycline – DoxC, cefoperazone – CefP, daptomycin – DapM
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after a 7-day and 14-day subculture (Fig. 3A, and 3C: pan-
els vi and xiv). Interestingly, there was no regrowth with 
the sample treated with Stevia A as there were only dead 
cells (100% elimination) after a 7-day subculture, and only 
a 10% increase in viable cells was observed after a sub-
culture for 14 days (Fig. 3A, and 3C: panels viii and xvi).
In Fig. 3A, the effectiveness of doxycycline and the 
three-antibiotic combination after a 7-day and a 14-day 
subculture was compared with Stevia A. A signifi cant re-
duction (p value ≤ 0.05) in the regrowth of Borrelia was 
found with Stevia A compared to doxycycline after a 14-
day subculture.
Direct microscopic counting confi rmed the SYBR 
Green I/PI assay and showed that drug-free controls and 
the negative controls (1× PBS and 25% alcohol) grew well 
in the 7-day and 14-day subcultures (Fig. 3B). Samples 
treated with doxycycline, cefoperazone, and the three-anti-
biotic combination produced ~2% viable cells after 7 days 
(Fig. 3B). Cefoperazone and the three-antibiotic combina-
tion produced ~1% viable cells after a 14-day subculture 
(Fig. 3B). However, there was an increase in viable cells 
by 68% treated with doxycycline after a 14-day subculture 
(Fig. 3B). Daptomycin treated cells were able to recover 
better than the other antibiotic counterparts with regrowth 
similar to the drug-free control in the 7- and 14-day sub-
cultures (Fig. 3B). Samples treated with Stevia A after a 
7-day subculture showed no signs of regrowth, and only 
1% of viable cells were observed after a 14-day subculture 
(Fig. 3B).
In Fig. 3B, the effectiveness of doxycycline and the 
three-antibiotic combination in the direct counting meth-
od, after a 7-day and a 14-day subculture, was compared 
with Stevia A. Signifi cant reduction (p value ≤ 0.01) in the 
regrowth of Borrelia was found with Stevia A compared to 
doxycycline after a 14-day subculture.
Stevia A significantly reduced Borrelia biofilms grown 
on plastic and collagen surfaces
Multiple morphological forms of B. burgdorferi, i.e, spi-
rochetal form, round bodies, and biofi lms have been ob-
served to have different antimicrobial susceptibilities [7]. 
In our previous publication, we characterized the antibiot-
ics sensitivity of the biofi lm form of B. burgdorferi and 
found that it is the most resistant form [7]. In this study, to 
evaluate the effect of antimicrobial agents on Borrelia bio-
fi lms grown on plastic and collagen surfaces, we stained 
the antimicrobial treated biofi lms with crystal violet to 
quantify the effectiveness of the different antimicrobial 
agents.
Biofi lms grown on plastic surface and treated with 
negative controls, 1× PBS or 25% alcohol, did not show 
reduction in the biofi lm masses compared to the untreated 
biofi lm control (Fig. 4). Biofi lms treated with doxycy-
cline, cefoperazone, daptomycin, and the three-antibiotic 
combination showed signifi cant increase in Borrelia bio-
fi lm mass compared to the drug-free control (Fig. 4). The 
treatment with Stevia A, however, signifi cantly reduced 
Borrelia biofi lms on plastic by ~40% compared to the 
control (Fig. 4).
Biofi lms grown on collagen-coated surface show that 
the treatment with negative control, 1× PBS or 25% al-
cohol, did not show reduction in the biofi lm masses com-
pared to the control (Fig. 4). Treatments with doxycycline 
and daptomycin did not have any signifi cant effect on 
Borrelia biofi lm mass (Fig. 4). There was an increase in 
Borrelia biofi lms grown on collagen when treated with 
cefoperazone, and in contrast, there was a 10% reduction 
observed in these biofi lms when treated with the three-
antibiotic combination compared to the control (Fig. 4). 
In addition, biofi lms treated with Stevia A also showed 
signifi cant reduction on collagen by ~34% compared to 
the control (Fig. 4). In order to assess the effectiveness of 
doxycycline and the three-antibiotic combination to Stevia 
A, the results in Fig. 4 showed that there was a signifi cant 
reduction in the total Borrelia biomass grown on plastic 
and collagen surfaces by Stevia A compared to doxycy-
cline and the three-antibiotic combination (p value ≤ 0.01).
Stevia A decreases viability in attached Borrelia biofilms
In order to directly observe the viability of attached bio-
fi lms after antimicrobial treatment, we stained the treated 
biofi lms using a mixture of SYBR Green I and propidium 
iodide (live/dead stains). The Borrelia biofi lms treated 
with 1× PBS and 25% alcohol were large and compact, 
mostly staining green, depicting that the biofi lm was live 
Fig. 4. Susceptibility of Borrelia burgdorferi biofilms grown 
on plastic and collagen-coated surface to antimicrobial agents 
after a three-day treatment determined by crystal violet assay. 
Doxycycline (DoxC) was used as a positive control. 1× PBS and 
25% alcohol were used as negative controls, respectively. All 
antibiotics individually as well as in combination were used at a 
concentration of 10 μg/ml. Stevia A was used at a concentration 
of 1.2 μg/ml. n = 3 ± SD, *p ≤ 0.05, **p ≤ 0.01 compared to the 
control. n = 3 ± SD, +p ≤ 0.05, ++p ≤ 0.01 (doxycycline compared 
to Stevia A). n = 3 ± SD, •p ≤ 0.05, • •p ≤ 0.01 (doxycycline 
compared to Stevia A). Abbreviations: doxycycline – DoxC, 
cefoperazone – CefP, daptomycin – DapM
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(Fig. 5: panels ii and iii). The biofi lms treated with cefo-
perazone were signifi cantly smaller compared to the bio-
fi lms treated with doxycycline, and both were green with 
small red spots indicating that they were alive (Fig. 5: pan-
els iv and v). The biofi lms treated with daptomycin were 
large and compact and stained mostly green with live cells 
(Fig. 5: panel vi), whereas the biofi lms treated with the 
antibiotic combination were made up with a mixture of 
live and dead cells with live cells predominating (Fig. 5: 
panel vii). Borrelia biofi lm treatment with Stevia A stained 
predominantly red, depicting that the biofi lm had mainly 
dead spirochetes and round bodies (Fig. 5: panel viii). The 
Fig. 5. Representative live/dead images of Borrelia biofilms treated with different antimicrobial agents followed by staining with 
SYBR Green I and PI dye mixture taken at 200× magnification. Doxycycline (DoxC) was used as a positive control. 1× sterile PBS 
and 25% alcohol were used as negative controls, respectively. All antibiotics individually as well as in combination were used at a 
concentration of 10 μg/ml. Stevia A was used at a concentration of 1.2 μg/ml. Scale bar −100 μm. Abbreviations: doxycycline – DoxC, 
cefoperazone – CefP, daptomycin – DapM
Fig. 6. Representative atomic force microscopy images showing the ultrastructural details of Borrelia biofilm before and after treatment 
with antimicrobial agents. The preparations of B. burgdorferi strain B31 biofilms on chamber slides are described in Materials and 
methods section. All biofilms were scanned at 0.4 Hz using contact mode and the individual Z ranges (height) are indicated next to 
each panel by means of a scale. The images were scanned using the Nanosurf Easyscan 2 software, and the images were processed 
using Gwyddion software. All antibiotics individually as well as in combination were used at a concentration of 10 μg/ml. Stevia A 
was used at a concentration of 1.2 μg/ml. Abbreviations: doxycycline – DoxC, cefoperazone – CefP, Daptomycin – DapM
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morphology of the Stevia A treated biofi lm was small and 
loosely packed compared to the biofi lms treated with anti-
biotics (Fig. 5: panel viii).
AFM analysis shows loose morphology with biofilms 
treated with Stevia A
The atomic force microscopic images, which are 3D ren-
dered and digitally colored for improved visualization, 
show the ultra structural features in the biofi lms before 
and after treatment with antimicrobial agents. The red 
color shows the highest peak in the biofi lms, which mainly 
indicates the potential presence of biofi lm EPS matrix. The 
drug-free control had a very compact and rigid structure 
with notable EPS buildup (Fig. 6: panel i). The biofi lms 
treated with doxycycline, cefoperazone, daptomycin, and 
the three-antibiotic combination were similar to the con-
trol having compact structure with more potential layers 
of EPS (Fig. 6: panels ii–v). Interestingly, Stevia treated 
biofi lms have a very loose structure with the EPS layer 
almost not formed (Fig. 6: panel vi).
Discussion
In this study, we evaluated the antimicrobial potential 
of whole leaf Stevia extracts against the Lyme disease 
causing pathogen, B. burgdorferi. We compared the 
antimicrobial effect of Stevia with antibiotics (doxycy-
cline, cefoperazone, daptomycin) and their combination, 
which were recently found effective against Borrelia 
persisters [31]. For this study, we have chosen to utilize 
a novel quantitative method developed by J. Feng et al. 
combined with our previously reported direct counting 
method [7, 30, 31, 46]. Findings from this study show 
that Stevia whole leaf extract, as an individual agent, 
was effective against all known morphological forms of 
B. burgdorferi.
In the preliminary screening experiment using differ-
ent extracts of Stevia, we demonstrated a signifi cant vari-
ation in the effectiveness of the alcohol extracts of Stevia 
(Stevia A, Stevia B, and Stevia C) on Borrelia persisters 
compared to the powder form of Stevia (Stevia D) and 
purifi ed Stevioside which did not show any effect (Fig. 1). 
We also found that one of the Stevia compounds, Stevia 
A, signifi cantly eliminated Borrelia persisters compared 
to other Stevia extracts (Fig. 1). This might be explained 
by the reported variations observed in the different phy-
tochemical concentrations of different Stevia extracts, 
which resulted from the growing conditions and agri-
cultural practices followed [47, 48]. Since Stevia A was 
effective in eliminating Borrelia persisters, Stevia A was 
chosen for further investigating the effectiveness on the 
different morphological forms of B. burgdorferi.
In the next set of experiments, we compared the ef-
fectiveness of Stevia A to the antibiotics and the three-
antibiotic combinations found effective in recent reports 
by J. Feng et al., [31] fi rst to Borrelia spirochetes and then 
the persisters using the quantitative method developed by 
J. Feng et al. and E. Sapi et al. We observed that Stevia 
A, even at a lower concentration (1.2 μg/ml), could sig-
nifi cantly eliminate the viability of early log phase and 
stationary cultures of B. burgdorferi using the SYBR 
Green I/ PI method (Fig. 2A, and 2C: panels viii and xvi) 
which was also confi rmed using the direct counting meth-
od (Fig. 2B, and 2C: panels viii and xvi). According to 
a report by J. Feng et al. (2015), daptomycin and cefo-
perazone, although effective against Borrelia persisters, 
could not completely eliminate the microcolony form of 
B. burgdorferi [30]. It was also observed from previous 
in vivo and in vitro studies that doxycycline was effec-
tive in eliminating the spirochetes but not the persisters 
of Borrelia [7, 16, 17, 30, 31]. However, J. Feng et al. 
also showed that the three-antibiotic combination (doxy-
cycline, cefoperazone, and daptomycin) was very potent 
in eliminating the stationary phase rich persisters of Bor-
relia [30]. In this study, we provided evidence that Stevia 
A, as an individual agent, was capable of eliminating the 
spirochetes and the persisters of Borrelia similar to the 
reported three-drug combination treatment. Our data also 
showed that the antibiotics in combination on the persist-
ers of Borrelia was indeed consistent with the previous 
study [30]; this result further confi rms the effectiveness 
of Stevia A.
In our previous studies, we characterized the biofi lm 
form of B. burgdorferi in vitro, and showed that it rep-
resents the most antibiotic resistant form [24]. It is also 
reported that biofi lms attached to a surface are protected 
from antibiotics or other antimicrobial agents [28, 29]. In 
this study, we also evaluated the effect of all antimicrobial 
agents on attached Borrelia biofi lms. Our results showed 
that Stevia A is very effective, in reducing attached Bor-
relia biofi lm mass on both plastic and collagen coated sur-
faces by ~40% (Fig. 4) whereas the individual antibiotics 
actually induced the size of the biofi lm mass (Fig. 4).
It was previously reported that certain antibiotics 
could indeed promote bacterial biofi lm formation [49]. 
One potential explanation is that cells in biofi lms are 
capable of protecting themselves from unfavorable an-
tibiotic environment [24, 28] by developing several de-
fensive mechanisms such as poor antibiotic penetration, 
phenotypic changes of cells forming in the biofi lm, the 
expression of effl ux pumps, and the presence of persister 
cells, which resist dying when exposed to antimicrobial 
agents [28, 29]. Persisters are a subpopulation of highly 
resistant cells, which are found among the normal cell 
population, and they are dormant and highly protected 
[28]. Studies show that small fraction of cells in biofi lms 
were unaffected after prolonged antibiotic treatment [29, 
53].
The obvious question on how Stevia could affect the 
highly resistant Borrelia biofi lm warrants further investi-
gation. In a study using a sugar alcohol, it was reported 
that xylitol acts as an antiplaque agent by disrupting the 
formation of biofi lms in the oral cavity [54]. In another 
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study, they showed that xylitol affects the production of 
adhesive polysaccharides of Streptococcus mutans [55]. 
It was previously shown that sugars prime the uptake of 
antibiotics in Staphylococcus aureus and Escherichia coli 
[56]. Based on these previous fi ndings, we hypothesize 
that Stevia could act as a sugar derivative, which might 
prime the uptake of the phytochemicals responsible for 
the antimicrobial effect and, thereby, disrupt the biofi lm 
structure. In support to our hypothesis, we also showed 
that the ultrastructure of Stevia A-treated biofi lm has very 
loose morphology with large shallow pits compared to the 
compact structure of biofi lms treated with doxycycline, 
cefoperazone, daptomycin, and the antibiotic combina-
tion (Fig. 6: panels ii–vi).
To further confi rm the effectiveness of Stevia, we per-
formed long-term subculture experiments using the an-
timicrobial treated, stationary phase predominated with 
Borrelia persisters by transferring a population of the 
treated cells into fresh culture medium to observe if vi-
able cells can regrow after a 7-day and a 14-day period in 
the absence of antimicrobial agent. The natural antimicro-
bial agent (Stevia A) was shown to be effective with no 
regrowth of viable cells after a 7-day subculture and with 
only 10% increase in viable cells after a 14-day subcul-
ture. The effects of the three-antibiotic combination, when 
compared to Stevia A, regrew with 5% and 11% of viable 
cells as detected using the SYBR Green I/PI method and 
confi rmed by fl uorescent microscopy (Fig. 3A, and 3B: 
panels vii, viii, xv, and xvi). We also observed that Bor-
relia treated with doxycycline and cefoperazone, which 
did not show any signifi cant effect against the persisters 
(Fig. 2A, 2B, and 2C: panels xii and xiii), recovering with 
only 13% and 6% viable cells after a 7-day subculture 
(Fig. 3A, and 3C: panels iv and v). One possible explana-
tion for this phenomenon could be that antibiotic sensitiv-
ity might have been restored when bacteria are dispersed 
from a biofi lm during favorable conditions [28].
Stevia leaf extract is a widely used sugar substitute 
[39–41, 57]; however, recent studies show that one of 
the major glycosides, stevioside, could have antimi-
crobial effect against Bacillus cereus, Bacillus subtilis, 
Klebsiella pneumoniae, and Pseudomonas aeruginosa 
[42]. These antimicrobial studies used a high concentra-
tion of purifi ed stevioside, and in our study, we achieved 
similar antimicrobial effect against Borrelia by using a 
lower concentration of the whole leaf extract. Our data 
with purifi ed Stevioside did not show any signifi cant an-
timicrobial effect on Borrelia spirochetes and persisters 
compared to the whole leaf extracts of Stevia (Fig. 1). 
This fi nding suggests that other components within the 
Stevia whole leaf extract could have antimicrobial activ-
ity against B. burgdorferi, which are yet to be identifi ed in 
future studies. In a good agreement with our fi ndings, Ste-
via leaf extract has also demonstrated antimicrobial activ-
ity against pathogens such as E. coli, S. aureus, Vibrio 
mimicus, Salmonella typhimurium, S. mutans, Bacillus 
subtilis, Shigella dysenteriae, and Vibrio cholera [38–42]. 
The next question is whether Stevia could be safely used 
as a therapeutic agent. Toxicological studies have shown 
that Stevia does not have mutagenic, teratogenic, or car-
cinogenic effects [57], and recent studies demonstrated 
its safety at high dietary intake levels [57–59]. In a study 
examining the mutagenicity of Stevioside and Steviol, it 
was noted that Stevioside at 10 mg/ml did not induce any 
mutation in S. typhimurium [60]. Apart from these stud-
ies, there are two important clinical studies based on the 
glycoproteins present in Stevia. In a randomized, double-
blinded study on Chinese men and women experiencing 
mild hyper tension, it was reported that the glycoprotein 
stevioside decreased the systolic and diastolic blood pres-
sure and also improved quality of life without causing any 
adverse effects compared to the placebo [44]. In another 
study, the acute effects of stevioside in type 2 diabetic pa-
tients were analyzed [45]. Compared to the control group, 
stevioside reduces postprandial blood glucose levels in 
type 2 diabetic patients [45]. It was noted that both these 
studies used an encapsulated powdered form of stevioside 
and whole leaf extract that had been taken orally [44, 45]. 
It was also observed that one of the clinical studies used a 
whole leaf preparation, which contained 91% stevioside, 
4% rebaudioside A, and 5% of other derivatives of stevio-
side [45]. The outcome from these clinical studies dem-
onstrates that the patients did not encounter any adverse 
effects from the use of stevioside [44, 45]. Although the 
safeness of Stevia is widely studied, more in vivo studies 
are warranted before Stevia could be used as an antimi-
crobial agent for any infectious diseases.
Our future goal is to further investigate the indi-
vidual components of whole leaf Stevia extract against 
B. burgdorferi and to identify the most effective compo-
nent responsible for its signifi cant antimicrobial effect. 
In conclusion, the overall antimicrobial effectiveness of 
Stevia A extract on the different morphological forms of 
B. burgdorferi was comparable to the combination of cer-
tain antibiotics. Although the results of this preliminary 
study cannot be extrapolated directly to clinical practice, 
further follow-up studies are necessary which can address 
the safeness of Stevia and to further identify the most ef-
fective component(s) against Borrelia.
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